Listed

Aclaris Therapeutics, Inc.

ACRSNasdaqCIK 1557746HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.6m, Q2 FY2026
Operating income−$24.2m, Q2 FY2026
Net income−$21.5m, Q2 FY2026
Aclaris Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m9.3Revenue, Q3 FY2023, three months to 2023-09-30$9.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure17.6Revenue, Q4 FY2023, three months to 2023-12-31$17.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure2.4Revenue, Q1 FY2024, three months to 2024-03-31$2.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure2.8Revenue, Q2 FY2024, three months to 2024-06-30$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure4.3Revenue, Q3 FY2024, three months to 2024-09-30$4.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure9.2Revenue, Q4 FY2024, three months to 2024-12-31$9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure1.5Revenue, Q1 FY2025, three months to 2025-03-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure1.8Revenue, Q2 FY2025, three months to 2025-06-30$1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure3.3Revenue, Q3 FY2025, three months to 2025-09-30$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure1.3Revenue, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure2.0Revenue, Q1 FY2026, three months to 2026-03-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure1.6Revenue, Q2 FY2026, three months to 2026-06-30$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Cost of revenue$m0.8Cost of revenue, Q3 FY2023, three months to 2023-09-30$848.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure0.7Cost of revenue, Q4 FY2023, three months to 2023-12-31$725.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure0.8Cost of revenue, Q1 FY2024, three months to 2024-03-31$809.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure0.6Cost of revenue, Q2 FY2024, three months to 2024-06-30$624.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure0.7Cost of revenue, Q3 FY2024, three months to 2024-09-30$654.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure0.7Cost of revenue, Q4 FY2024, three months to 2024-12-31$705.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure0.5Cost of revenue, Q1 FY2025, three months to 2025-03-31$506.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure0.5Cost of revenue, Q2 FY2025, three months to 2025-06-30$515.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure0.5Cost of revenue, Q3 FY2025, three months to 2025-09-30$538.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure0.5Cost of revenue, Q4 FY2025, three months to 2025-12-31$532.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure0.4Cost of revenue, Q1 FY2026, three months to 2026-03-31$395.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure0.2Cost of revenue, Q2 FY2026, three months to 2026-06-30$218.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Gross profit$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m23.9Research and development, Q3 FY2023, three months to 2023-09-30$23.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure26.6Research and development, Q4 FY2023, three months to 2023-12-31$26.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure9.8Research and development, Q1 FY2024, three months to 2024-03-31$9.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure8.8Research and development, Q2 FY2024, three months to 2024-06-30$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure6.0Research and development, Q3 FY2024, three months to 2024-09-30$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure9.0Research and development, Q4 FY2024, three months to 2024-12-31$9.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure11.6Research and development, Q1 FY2025, three months to 2025-03-31$11.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure11.4Research and development, Q2 FY2025, three months to 2025-06-30$11.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure13.0Research and development, Q3 FY2025, three months to 2025-09-30$13.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure16.6Research and development, Q4 FY2025, three months to 2025-12-31$16.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure15.7Research and development, Q1 FY2026, three months to 2026-03-31$15.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure18.1Research and development, Q2 FY2026, three months to 2026-06-30$18.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Operating income$m(31.6)Operating income, Q3 FY2023, three months to 2023-09-30−$31.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure(4.0)Operating income, Q4 FY2023, three months to 2023-12-31−$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure(18.9)Operating income, Q1 FY2024, three months to 2024-03-31−$18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure(12.9)Operating income, Q2 FY2024, three months to 2024-06-30−$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure(10.5)Operating income, Q3 FY2024, three months to 2024-09-30−$10.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(99.7)Operating income, Q4 FY2024, three months to 2024-12-31−$99.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(18.1)Operating income, Q1 FY2025, three months to 2025-03-31−$18.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(18.4)Operating income, Q2 FY2025, three months to 2025-06-30−$18.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(17.1)Operating income, Q3 FY2025, three months to 2025-09-30−$17.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(22.7)Operating income, Q4 FY2025, three months to 2025-12-31−$22.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(22.2)Operating income, Q1 FY2026, three months to 2026-03-31−$22.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(24.2)Operating income, Q2 FY2026, three months to 2026-06-30−$24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Net income$m(29.3)Net income, Q3 FY2023, three months to 2023-09-30−$29.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure(1.5)Net income, Q4 FY2023, three months to 2023-12-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure(16.9)Net income, Q1 FY2024, three months to 2024-03-31−$16.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(11.0)Net income, Q2 FY2024, three months to 2024-06-30−$11.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(7.6)Net income, Q3 FY2024, three months to 2024-09-30−$7.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(96.6)Net income, Q4 FY2024, three months to 2024-12-31−$96.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(15.1)Net income, Q1 FY2025, three months to 2025-03-31−$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(15.4)Net income, Q2 FY2025, three months to 2025-06-30−$15.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(14.6)Net income, Q3 FY2025, three months to 2025-09-30−$14.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(19.8)Net income, Q4 FY2025, three months to 2025-12-31−$19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(19.8)Net income, Q1 FY2026, three months to 2026-03-31−$19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(21.5)Net income, Q2 FY2026, three months to 2026-06-30−$21.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Diluted EPS$ per share(0.41)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figurenot reported(0.24)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure(0.15)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure(0.11)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figurenot reported(0.12)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(0.13)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(0.12)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figurenot reported(0.15)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(0.15)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Basic EPS$ per share(0.41)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figurenot reported(0.24)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure(0.15)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure(0.11)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figurenot reported(0.12)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(0.13)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(0.12)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figurenot reported(0.15)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(0.15)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure

Balance sheet

Cash and equivalents$19.2m, Q2 FY2026
Shareholders' equity$124.6m, Q2 FY2026
Aclaris Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m39.0Cash and equivalents, Q3 FY2023, at 2023-09-30$39.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-06, accession 0001558370-23-017660.Report this figure39.9Cash and equivalents, FY2023, at 2023-12-31$39.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure35.8Cash and equivalents, Q1 FY2024, at 2024-03-31$35.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001558370-24-007069.Report this figure22.8Cash and equivalents, Q2 FY2024, at 2024-06-30$22.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-07, accession 0001558370-24-011376.Report this figure47.7Cash and equivalents, Q3 FY2024, at 2024-09-30$47.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure24.6Cash and equivalents, FY2024, at 2024-12-31$24.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure30.4Cash and equivalents, Q1 FY2025, at 2025-03-31$30.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure25.4Cash and equivalents, Q2 FY2025, at 2025-06-30$25.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure25.3Cash and equivalents, Q3 FY2025, at 2025-09-30$25.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure20.0Cash and equivalents, FY2025, at 2025-12-31$20.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure28.7Cash and equivalents, Q1 FY2026, at 2026-03-31$28.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure19.2Cash and equivalents, Q2 FY2026, at 2026-06-30$19.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Current assets$m123Current assets, Q3 FY2023, at 2023-09-30$123.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-06, accession 0001558370-23-017660.Report this figure129Current assets, FY2023, at 2023-12-31$128.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure135Current assets, Q1 FY2024, at 2024-03-31$135.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007069.Report this figure118Current assets, Q2 FY2024, at 2024-06-30$117.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0001558370-24-011376.Report this figure132Current assets, Q3 FY2024, at 2024-09-30$132.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure126Current assets, FY2024, at 2024-12-31$126.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure109Current assets, Q1 FY2025, at 2025-03-31$108.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure104Current assets, Q2 FY2025, at 2025-06-30$104.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure101Current assets, Q3 FY2025, at 2025-09-30$100.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure96.3Current assets, FY2025, at 2025-12-31$96.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure110Current assets, Q1 FY2026, at 2026-03-31$110.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure97.8Current assets, Q2 FY2026, at 2026-06-30$97.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Total assets$m218Total assets, Q3 FY2023, at 2023-09-30$218.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-06, accession 0001558370-23-017660.Report this figure197Total assets, FY2023, at 2023-12-31$197.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure174Total assets, Q1 FY2024, at 2024-03-31$174.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001558370-24-007069.Report this figure161Total assets, Q2 FY2024, at 2024-06-30$161.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0001558370-24-011376.Report this figure182Total assets, Q3 FY2024, at 2024-09-30$182.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure220Total assets, FY2024, at 2024-12-31$220.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure198Total assets, Q1 FY2025, at 2025-03-31$198.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure189Total assets, Q2 FY2025, at 2025-06-30$189.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure176Total assets, Q3 FY2025, at 2025-09-30$175.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure160Total assets, FY2025, at 2025-12-31$160.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure199Total assets, Q1 FY2026, at 2026-03-31$198.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure180Total assets, Q2 FY2026, at 2026-06-30$179.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Current liabilities$m27.3Current liabilities, Q3 FY2023, at 2023-09-30$27.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-06, accession 0001558370-23-017660.Report this figure31.0Current liabilities, FY2023, at 2023-12-31$31.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure20.1Current liabilities, Q1 FY2024, at 2024-03-31$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007069.Report this figure15.7Current liabilities, Q2 FY2024, at 2024-06-30$15.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0001558370-24-011376.Report this figure18.8Current liabilities, Q3 FY2024, at 2024-09-30$18.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure31.6Current liabilities, FY2024, at 2024-12-31$31.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure21.5Current liabilities, Q1 FY2025, at 2025-03-31$21.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure26.8Current liabilities, Q2 FY2025, at 2025-06-30$26.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure25.6Current liabilities, Q3 FY2025, at 2025-09-30$25.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure28.6Current liabilities, FY2025, at 2025-12-31$28.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure27.4Current liabilities, Q1 FY2026, at 2026-03-31$27.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure28.2Current liabilities, Q2 FY2026, at 2026-06-30$28.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Total liabilities$m62.0Total liabilities, Q3 FY2023, at 2023-09-30$62.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-06, accession 0001558370-23-017660.Report this figure40.2Total liabilities, FY2023, at 2023-12-31$40.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure32.1Total liabilities, Q1 FY2024, at 2024-03-31$32.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001558370-24-007069.Report this figure27.2Total liabilities, Q2 FY2024, at 2024-06-30$27.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0001558370-24-011376.Report this figure52.2Total liabilities, Q3 FY2024, at 2024-09-30$52.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure64.8Total liabilities, FY2024, at 2024-12-31$64.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure54.0Total liabilities, Q1 FY2025, at 2025-03-31$54.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure57.4Total liabilities, Q2 FY2025, at 2025-06-30$57.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure55.4Total liabilities, Q3 FY2025, at 2025-09-30$55.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure57.4Total liabilities, FY2025, at 2025-12-31$57.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure55.1Total liabilities, Q1 FY2026, at 2026-03-31$55.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure55.1Total liabilities, Q2 FY2026, at 2026-06-30$55.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m156Shareholders' equity, Q3 FY2023, at 2023-09-30$156.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure157Shareholders' equity, FY2023, at 2023-12-31$157.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure142Shareholders' equity, Q1 FY2024, at 2024-03-31$142.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure134Shareholders' equity, Q2 FY2024, at 2024-06-30$133.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure130Shareholders' equity, Q3 FY2024, at 2024-09-30$130.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure156Shareholders' equity, FY2024, at 2024-12-31$155.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure144Shareholders' equity, Q1 FY2025, at 2025-03-31$144.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure132Shareholders' equity, Q2 FY2025, at 2025-06-30$131.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure120Shareholders' equity, Q3 FY2025, at 2025-09-30$120.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure103Shareholders' equity, FY2025, at 2025-12-31$103.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure144Shareholders' equity, Q1 FY2026, at 2026-03-31$143.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure125Shareholders' equity, Q2 FY2026, at 2026-06-30$124.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure

Cash flow

Operating cash flow−$19.8m, Q2 FY2026
Capital expenditure$58.0k, Q2 FY2026
Aclaris Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(24.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$24.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001558370-24-014646. Derived: 9-month figure less the 6-month figure.Report this figure(6.8)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$6.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure(20.8)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$20.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure(12.3)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$12.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001558370-25-010789. Derived: 6-month figure less the 3-month figure.Report this figure22.0Operating cash flow, Q3 FY2024, three months to 2024-09-30$22.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Report this figure(8.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(13.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(10.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure(10.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Report this figure(13.1)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(18.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(19.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$19.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$84.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0001558370-24-014646. Derived: 9-month figure less the 6-month figure.Report this figure0.4Capital expenditure, Q4 FY2023, three months to 2023-12-31$441.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001558370-25-001819. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$135.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure(0.0)Capital expenditure, Q2 FY2024, three months to 2024-06-30−$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001558370-25-010789. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$43.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$21.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$23.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$58.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)142.74m, Q2 FY2026
Aclaris Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares66.7Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3066,675,337 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-06, accession 0001558370-23-017660.Report this figure66.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3166,872,778 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001558370-24-007069.Report this figure70.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3070,633,528 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0001558370-24-011376.Report this figure70.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3070,807,934 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001558370-24-014646.Report this figure71.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3171,074,858 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001558370-25-006993.Report this figure71.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3071,291,400 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001558370-25-010789.Report this figure71.4Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3071,381,731 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure122Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31122,390,303 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure123Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30122,580,967 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure123Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30122,619,311 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure129Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31128,810,050 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure143Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30142,736,848 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure

Shares outstanding: 147.20mShares outstanding, period not labelled, at 2026-07-31147,198,893 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.